Disease · MONDO_0002268

dyspepsia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. dyspepsia. Diseases, record MONDO_0002268. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002268

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: dyspepsia; Open Targets
Open Targets ID: MONDO_0002268; Open Targets
Other names: dyspepsia, indigestion, indigestion, indigestion NOS; Open Targets
Disease Ontology: DOID:2321; Disease Ontology
MeSH: D004415; MeSH
NCI Thesaurus: C26756; NCI Thesaurus
Highest stage of its drugs: Approval, for 18 of its 45 drugs, from DailyMed, PMDA and TTD; Open Targets

Drugs45

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TEGASEROD	CHEMBL76370	Small molecule	Approval	TTD, at withdrawal	6	5	5	Drugs and targets
OMEPRAZOLE	CHEMBL1503	Small molecule	Approval	DailyMed	6	3	3	Drugs and targets
ACOTIAMIDE HYDROCHLORIDE	CHEMBL2107308	Small molecule	Approval	PMDA	4	3	3	Drugs and targets
CALCIUM CARBONATE	CHEMBL1200539	Small molecule	Approval	DailyMed	18	1	1	Drugs and targets
FAMOTIDINE	CHEMBL902	Small molecule	Approval	DailyMed	4	1	1	Drugs and targets
MAGNESIUM HYDROXIDE	CHEMBL1200718	Small molecule	Approval	DailyMed	19	0	0	Drugs and targets
ALUMINUM HYDROXIDE	CHEMBL1200706	Small molecule	Approval	DailyMed	15	0	0	Drugs and targets
SODIUM BICARBONATE	CHEMBL1353	Small molecule	Approval	DailyMed	15	0	0	Drugs and targets
BISMUTH SUBSALICYLATE	CHEMBL1120	Small molecule	Approval	DailyMed	4	0	0	Drugs and targets
DEXLANSOPRAZOLE	CHEMBL1201863	Small molecule	Approval	DailyMed	4	0	0	Drugs and targets

1 to 10 of 45

See all 45 drugs

Targets47

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ATP4A	Potassium-transporting ATPase	7	Potassium-transporting ATPase inhibitor	Approval	https://conductscience.org/library/genes/495	Drugs and targets
ATP4B	Potassium-transporting ATPase	7	Potassium-transporting ATPase inhibitor	Approval	https://conductscience.org/library/genes/496	Drugs and targets
HRH2	Histamine H2 receptor	5	Histamine H2 receptor antagonist	Approval	https://conductscience.org/library/genes/3274	Drugs and targets
DRD2	D(2) dopamine receptor	4	Dopamine D2 receptor antagonist	Approval	https://conductscience.org/library/genes/1813	Drugs and targets
ACHE	Acetylcholinesterase	3	Acetylcholinesterase inhibitor	Approval	https://conductscience.org/library/genes/43	Drugs and targets
HTR3A	5-hydroxytryptamine receptor 3A	3	Serotonin 3 (5-HT3) receptor antagonist; Serotonin 3a (5-HT3a) receptor antagonist	Approval	https://conductscience.org/library/genes/3359	Drugs and targets
HTR4	5-hydroxytryptamine receptor 4	3	Serotonin 4 (5-HT4) receptor agonist; Serotonin 4 (5-HT4) receptor partial agonist	Approval	https://conductscience.org/library/genes/3360	Drugs and targets
PTGS1	Cyclooxygenase	2	Cyclooxygenase inhibitor	Approval	https://conductscience.org/library/genes/5742	Drugs and targets
PTGS2	Cyclooxygenase	2	Cyclooxygenase inhibitor	Approval	https://conductscience.org/library/genes/5743	Drugs and targets
CACNA1A	Voltage-gated calcium channel	1	Voltage-gated calcium channel modulator	Phase 3	https://conductscience.org/library/genes/773	Drugs and targets

1 to 10 of 47

See all 47 targets

Trials35

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01089543	A Study of E3810 for Japanese Subjects With Functional Dyspepsia (SAMURAI Study: Suppression of Acid Milieu With Rabeprazole Improving Functional Dyspepsia ) (Study E3810-J081-204)	Phase 2	338	2013-11-19	Functional Dyspepsia	RABEPRAZOLE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT03941288	Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia	Phase 2	92	2024-02-13	Gastroparesis, Dyspepsia	CANNABIDIOL	Its record names the disease	ClinicalTrials.gov
NCT01593592	Lactobacillus Reuteri in Management of Helicobacter Pylori Infection in Dyspeptic Patients	Not applicable	70	2015-08-17	Helicobacter Pylori Infection	AMOXICILLIN, CLARITHROMYCIN, OMEPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT00232024	Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia	Phase 3	1,296		Dyspepsia	TEGASEROD	Its record names the disease	ClinicalTrials.gov
NCT00232089	Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia	Phase 3	1,296		Dyspepsia	TEGASEROD	Its record names the disease	ClinicalTrials.gov
NCT00251992	Nexium Dyspepsia/AST	Phase 3	1,200		Gastrointestinal Disease, Signs and Symptoms, Digestive, Dyspepsia	ESOMEPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT00761358	To Verify the Efficacy of Z-338 in Subjects With Functional Dyspepsia	Phase 3	820		Functional Dyspepsia	ACOTIAMIDE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00247715	Comparison of a "Step-Up" Versus a "Step-Down" Treatment Strategy for Patients With New Onset Dyspepsia in General Practice (The DIAMOND-Study)	Not applicable	664		Dyspepsia, Gastrointestinal Diseases	ALGELDRATE, MAGNESIUM OXIDE, PANTOPRAZOLE, RANITIDINE	Its record names the disease	ClinicalTrials.gov
NCT00272103	Itopride in Functional Dyspepsia:a Dose Finding Study	Phase 2/3	500		Functional Dyspepsia	ITOPRIDE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT04069286	EFFICACY OF ORAL AROEIRA (Schinus Terebinthifolia Raddi) COMPARED TO OMEPRAZOLE IN DYSPEPPSIA	Phase 3	474		Dyspepsia	OMEPRAZOLE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 35

See all 35 trials

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Lactobacillus Reuteri Group vs Control Group: The Secondary End Point Was the Development of Severe Adverse Effects to the Used Medications and Dietary Supplements.	0 of 35	0 of 35	70	NCT01593592	Trial comparisons
Lactobacillus Reuteri Group vs Control Group: Eradication of H Pylori Infection 4 Weeks After Completion of Therapy	26 of 35	23 of 35	70	NCT01593592	Trial comparisons
Lactobacillus Reuteri Group vs Control Group: serious adverse events	0 of 35	0 of 35	70	NCT01593592	Trial comparisons
Functional Dyspepsia - Cannabidiol vs Functional Dyspepsia - Placebo: Weekly Global Symptom Assessment	12 of 25	11 of 23	48	NCT03941288	Trial comparisons

Papers from its trials28

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
32350723	RESULT	1	PubMed
31916648	RESULT	1	PubMed
31111585	RESULT	1	PubMed
30203587	RESULT	1	PubMed
28497487	RESULT	1	PubMed
28191328	RESULT	1	PubMed
27185079	RESULT	1	PubMed
20616418	RESULT	1	PubMed
18616658	RESULT	1	PubMed
17608775	RESULT	1	PubMed

1 to 10 of 28

See all 28 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002268

GET https://conductscience.org/api/diseases/v1/MONDO_0002268/drugs?page=2

API reference For AI assistants